CONTACT INFORMATION http://www.loyola.org
Michael Nishimura
Ph.D.
  • Professor
  • Associate Director, Oncology Institute and Cancer Center Translational Research
  • Program Director, Immunologic Therapeutics
  • Surgical Research
Publications

Immune Responses In A Mouse Model Of Vitiligo With Spontaneous Epidermal De- And RepigmentationEby,J. M.; Kang,H. K.; Klarquist,J.; Chatterjee,S.; Mosenson,J. A.; Nishimura,M. I.; Garrett-Mayer,E.; Jack Longley,B.; Engelhard,V. H.; Mehrotra,S.; Le Poole,I. C.Pigment Cell & Melanoma Research 2014 ; ( ):

A Quantitative Increase in Regulatory T Cells Controls Development of VitiligoChatterjee,S.; Eby,J.; Al-Khami,A. A.; Soloshchenko,M.; Kang,H. K.; Kaur,N.; Naga,O.; Murali,A.; Nishimura,M. I.; Caroline Le Poole,I.; Mehrotra,S.The Journal of investigative dermatology 2013 ; ( ):

Mutant HSP70 reverses autoimmune depigmentation in vitiligoMosenson,J. A.; Zloza,A.; Nieland,J. D.; Garrett-Mayer,E.; Eby,J. M.; Huelsmann,E. J.; Kumar,P.; Denman,C. J.; Lacek,A. T.; Kohlhapp,F. J.; Alamiri,A.; Hughes,T.; Bines,S. D.; Kaufman,H. L.; Overbeck,A.; Mehrotra,S.; Hernandez,C.; Nishimura,M. I.; Guevara-Patino,J. A.; Le Poole,I. C.Science translational medicine 2013 ;5(174):174ra28

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in miceMehrotra,S.; Al-Khami,A. A.; Klarquist,J.; Husain,S.; Naga,O.; Eby,J. M.; Murali,A. K.; Lyons,G. E.; Li,M.; Spivey,N. D.; Norell,H.; Martins da Palma,T.; Onicescu,G.; Diaz-Montero,C. M.; Garrett-Mayer,E.; Cole,D. J.; Le Poole,I. C.; Nishimura,M. I.Journal of immunology (Baltimore, Md.: 1950) 2012 ;189(4):1627-1638

CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-beta (TGF-beta)-mediated suppressionZloza,A.; Jagoda,M. C.; Lyons,G. E.; Graves,M. C.; Kohlhapp,F. J.; O'Sullivan,J. A.; Lacek,A. T.; Nishimura,M. I.; Guevara-Patino,J. A.Cancer immunology, immunotherapy : CII 2011 ;60(2):291-297

Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivityZhang,Y.; Liu,Y.; Moxley,K. M.; Golden-Mason,L.; Hughes,M. G.; Liu,T.; Heemskerk,M. H.; Rosen,H. R.; Nishimura,M. I.PLoS Pathogens 2010 ;6(7):e1001018

Reduced skin homing by functional Treg in vitiligoKlarquist,J.; Denman,C. J.; Hernandez,C.; Wainwright,D. A.; Strickland,F. M.; Overbeck,A.; Mehrotra,S.; Nishimura,M. I.; Le Poole,I. C.Pigment Cell & Melanoma Research 2010 ;23(2):276-286

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responsesKoya,R. C.; Mok,S.; Comin-Anduix,B.; Chodon,T.; Radu,C. G.; Nishimura,M. I.; Witte,O. N.; Ribas,A.Proceedings of the National Academy of Sciences of the United States of America 2010 ;107(32):14286-14291

Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.Klarquist,J.; Barfuss,A.; Kandala,S.; Reust,M. J.; Braun,R. K.; Hu,J.; Dilling,D. F.; McKee,M. D.; Boissy,R. E.; Love,R. B.; Nishimura,M. I.; Le Poole,I. C.American Journal of Pathology 2009 ;175(6):2463-2472

Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognitionMoore,T. V.; Lyons,G. E.; Brasic,N.; Roszkowski,J. J.; Voelkl,S.; Mackensen,A.; Kast,W. M.; Le Poole,I. C.; Nishimura,M. I.Cancer immunology, immunotherapy : CII 2009 ;58(5):719-728

T cell immunotherapyMcKee,M. D.; Fichera,A.; Nishimura,M. I.Frontiers in bioscience : a journal and virtual library 2007 ;12( ):919-932

Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cellsKaplan,B. L.; Norell,H.; Callender,G. G.; Ohlum,T.; Kiessling,R.; Nishimura,M. I.Cancer immunology, immunotherapy : CII 2006 ;55(6):653-662

Identification of a hepatitis C virus-reactive T cell receptor that does not require CD8 for target cell recognitionCallender,G. G.; Rosen,H. R.; Roszkowski,J. J.; Lyons,G. E.; Li,M.; Moore,T.; Brasic,N.; McKee,M. D.; Nishimura,M. I.Hepatology (Baltimore, Md.) 2006 ;43(5):973-981

Influence of human CD8 on antigen recognition by T-cell receptor-transduced cellsLyons,G. E.; Moore,T.; Brasic,N.; Li,M.; Roszkowski,J. J.; Nishimura,M. I.Cancer research 2006 ;66(23):11455-11461

T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cellsLyons,G. E.; Roszkowski,J. J.; Man,S.; Yee,C.; Kast,W. M.; Nishimura,M. I.Cancer immunology, immunotherapy : CII 2006 ;55(9):1142-1150

Therapeutic implications of autoimmune vitiligo T cellsOyarbide-Valencia,K.; van den Boorn,J. G.; Denman,C. J.; Li,M.; Carlson,J. M.; Hernandez,C.; Nishimura,M. I.; Das,P. K.; Luiten,R. M.; Le Poole,I. C.Autoimmunity Reviews 2006 ;5(7):486-492

Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cellsFujii,S.; Nishimura,M. I.; Lotze,M. T.Cancer science 2005 ;96(12):897-902

Recognition of host immune activation by Pseudomonas aeruginosaWu,L.; Estrada,O.; Zaborina,O.; Bains,M.; Shen,L.; Kohler,J. E.; Patel,N.; Musch,M. W.; Chang,E. B.; Fu,Y. X.; Jacobs,M. A.; Nishimura,M. I.; Hancock,R. E.; Turner,J. R.; Alverdy,J. C.Science (New York, N.Y.) 2005 ;309(5735):774-777

T cell avidity and tumor recognition: implications and therapeutic strategiesMcKee,M. D.; Roszkowski,J. J.; Nishimura,M. I.JOURNAL OF TRANSLATIONAL MEDICINE 2005 ;3( ):35

Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptorRoszkowski,J. J.; Lyons,G. E.; Kast,W. M.; Yee,C.; Van Besien,K.; Nishimura,M. I.Cancer research 2005 ;65(4):1570-1576

Antigen recognition and T-cell biologyNishimura,M. I.; Roszkowski,J. J.; Moore,T. V.; Brasic,N.; McKee,M. D.; Clay,T. M.Cancer treatment and research 2005 ;123( ):37-59

A new murine tumor model for studying HLA-A2-restricted anti-tumor immunityKaplan,B. L.; Moore,T. V.; Schreiber,K.; Callender,G. G.; Schreiber,H.; Nishimura,M. I.Cancer letters 2005 ;224(1):153-166

Retroviral transduction of peptide stimulated t cells can generate dual t cell receptor-expressing (bifunctional) t cells reactive with two defined antigensLangerman,A.; Callender,G. G.; Nishimura,M. I.JOURNAL OF TRANSLATIONAL MEDICINE 2004 ;2(1):42

Cervical cancer vaccines: recent advances in HPV researchEiben,G. L.; da Silva,D. M.; Fausch,S. C.; Le Poole,I. C.; Nishimura,M. I.; Kast,W. M.Viral immunology 2003 ;16(2):111-121

CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cellRoszkowski,J. J.; Yu,D. C.; Rubinstein,M. P.; McKee,M. D.; Cole,D. J.; Nishimura,M. I.Journal of immunology (Baltimore, Md.: 1950) 2003 ;170(5):2582-2589

Cutting edge: the NK cell receptor 2B4 augments antigen-specific T cell cytotoxicity through CD48 ligation on neighboring T cellsLee,K. M.; Bhawan,S.; Majima,T.; Wei,H.; Nishimura,M. I.; Yagita,H.; Kumar,V.Journal of immunology (Baltimore, Md.: 1950) 2003 ;170(10):4881-4885

Redirecting T lymphocyte specificity using T cell receptor genesKaplan,B. L.; Yu,D. C.; Clay,T. M.; Nishimura,M. I.International reviews of immunology 2003 ;22(3-4):229-253

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cellsSpiotto,M. T.; Yu,P.; Rowley,D. A.; Nishimura,M. I.; Meredith,S. C.; Gajewski,T. F.; Fu,Y. X.; Schreiber,H.Immunity 2002 ;17(6):737-747

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanomaDudley,M. E.; Wunderlich,J.; Nishimura,M. I.; Yu,D.; Yang,J. C.; Topalian,S. L.; Schwartzentruber,D. J.; Hwu,P.; Marincola,F. M.; Sherry,R.; Leitman,S. F.; Rosenberg,S. A.Journal of immunotherapy (Hagerstown, Md.: 1997) 2001 ;24(4):363-373